Compare
Prokidney Corp. vs Pluri Inc. vs Inhibrx Biosciences, Inc. vs Scinai Immunotherapeutics Ltd.
| Latest fiscal year | Prokidney Corp. PROK | Pluri Inc. PLUR | Inhibrx Biosciences, Inc. INBX | Scinai Immunotherapeutics Ltd. SCNI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $893.0K | $1.02M | $1.30M | $1.31M |
| Revenue growth (YoY) | n/m | -24.0% | +550.0% | +99.2% |
| Gross margin | n/a | 44.6% | n/a | -202.3% |
| Operating margin | n/m | n/m | n/m | -575.3% |
| Net margin | n/m | n/m | n/m | -633.6% |
| Net income | -$151.61M | -$23.82M | -$140.06M | -$8.31M |
| EPS (Diluted) | n/a | -$2.44 | -$9.04 | n/a |
| Operating cash flow | -$120.12M | -$19.59M | -$129.79M | -$6.03M |
| Free cash flow | -$135.31M | -$20.22M | -$129.82M | -$6.05M |
| Cash & equivalents | $108.54M | $3.53M | $124.22M | $1.66M |
| Total assets | $335.57M | $24.88M | $146.48M | $11.63M |
| Total liabilities | $34.78M | n/a | $138.49M | n/a |
| Shareholders' equity | -$1.01B | -$23.04M | $7.99M | $8.10M |
| Return on year-end equity | n/a | n/a | n/m | -102.5% |
| Shares outstanding | n/a | 10.82M | 14.58M | 13.87B |
Revenue, most recent five fiscal years
| Fiscal year | Prokidney Corp. | Pluri Inc. | Inhibrx Biosciences, Inc. | Scinai Immunotherapeutics Ltd. |
|---|---|---|---|---|
| Latest | $893.0K Ended 2025-12-31 | $1.02M Ended 2026-06-30 | $1.30M Ended 2025-12-31 | $1.31M Ended 2025-12-31 |
| 1 year earlier | $76.0K Ended 2024-12-31 | $1.34M Ended 2025-06-30 | $200.0K Ended 2024-12-31 | $658.0K Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $326.0K Ended 2024-06-30 | $1.80M Ended 2023-12-31 | n/a |
| 3 years earlier | $0 Ended 2022-12-31 | $287.0K Ended 2023-06-30 | n/a | n/a |
| 4 years earlier | n/a | $234.0K Ended 2022-06-30 | n/a | n/a |